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Abstract: T-cell mediated immune responses should be regulated to avoid the development of 
autoimmune or chronic inflammatory diseases. Several mechanisms have been described to 
regulate this process, namely death of overactivated T cells by cytokine deprivation, suppression by 
T regulatory cells (Treg), induction of expression of immune checkpoint molecules such as CTLA-4 
and PD-1, or activation-induced cell death (AICD). In addition, activated T cells release membrane 
microvesicles called exosomes during these regulatory processes. In this review, we revise the role 
of exosome secretion in the different pathways of immune regulation described to date and its 
importance in the prevention or development of autoimmune disease. The expression of membrane-
bound death ligands on the surface of exosomes during AICD or the more recently described 
transfer of miRNA or even DNA inside T-cell exosomes is a molecular mechanism that will be 
analyzed. 
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1. Mechanisms of Immune T Cell Tolerance 
The maintenance of immune homeostasis is dependent on immune tolerance towards self-
tissues and is a complex process, necessary to avoid autoimmunity. In the case of T cells, two types 
of tolerance are needed, central and peripheral tolerance. Central tolerance takes place during thymic 
maturation, achieving the deletion of autoreactive immature thymocytes, a process also known as 
negative selection [1]. Peripheral tolerance comprises several mechanisms acting on mature T cells in 
peripheral tissues or circulation [2]. Among the known T-cell peripheral tolerance mechanisms are 
the following: 
(i) If the antigen is presented by cells that are not professional antigen-presenting cells (APC), 
or by immature APC, they do not provide co-stimulation signals and induce T cell anergy [3–5]. 
(ii) The immunosuppressive activity of regulatory T cells (Treg) [6]. 
(iii) The regulated termination of T cell immune responses [7], which, in turn, is dependent on 
several complex mechanisms. In fact, other possible mechanisms could still be discovered.  
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On one hand, T cell activation results in the induction of the expression of negative regulators 
of its own activation, the so-called immune checkpoints. The first checkpoint molecule to be described 
was CTLA-4 [8]. CLTA-4 competes with CD80/CD86 for the T cell co-stimulator CD28 [9], and, in 
addition, transmit inhibitory signals inside T cells [10]. Immune regulation by CTLA-4 is important 
since CTLA-4 knockout mice develop fatal lymphoproliferative disorders [11] and mutations in the 
CTLA-4 gene have been associated in humans with an increased risk of autoimmune disease [12,13]. 
Another important checkpoint molecule is PD-1 [14], which is also expressed on the surface of T cells 
upon activation, and that, by binding to its ligands PD-L1 and PD-L2, activate tyrosine phosphatase 
activities promoting the turning off of tyrosine kinase-mediated activating signals [15]. This 
mechanism is important to down-modulate inflammation in peripheral tissues in a physiological 
manner [16]. The use of blocking anti-CTLA-4 and anti-PD-1 antibodies in the immunotherapy of 
cancer has given excellent results, and this has been recognized with the Nobel Prize 2018 granted to 
the pioneers in the field, Jim P. Allison and Tasuku Honjo [17]. Other immune checkpoint molecules 
that regulate immune function are LAG-2, TIM-3 or TIGIT [18]. 
On the other hand, the deprivation of immuno-stimulatory cytokines such as IL-7, IL-2 and IL-
15 due to T cell migration to peripheral tissues from spleen or lymph nodes is the main cause of 
down-modulation of T cell responses, especially those mediated by CD8+ T cells, unable to produce 
their own cytokines [19]. Bim, a BH3-only, pro-apoptotic member of the Bcl-2 family, is the main 
regulator of this process, and defects in its expression are associated with autoimmunity [20,21]. 
Finally, the termination of immune responses is also mediated by activation-induced cell death 
(AICD) of T cells. The main regulator of AICD is the Fas/Fas ligand (FasL) system [22,23], and 
mutations in Fas or FasL are the cause of the autoimmune lympho-proliferative syndromes (ALPS) 
[24]. Apo2L/TRAIL (Apo2 Ligand/TNF-related apoptosis-inducing ligand) is another member of the 
FasL death ligand family and it has also been implicated in human T cell AICD [25,26]. It rather 
functions as a fine-tuning modulator of IL2-dependent CD8+ T cell proliferation [27] or in the 
elimination of CD8+ T cells activated in the absence of CD4+ T cell help [28]. No autoimmune disease 
is known to be associated with TRAIL mutations, although TRAIL-knockout mice are more sensitive 
to the induction of experimental autoimmune diseases [29]. 
2. Exosomes in Immune Regulation 
2.1. Exosomes in Immune Cells 
Exosomes are secreted extracellular membrane vesicles, with a particular lipid and protein 
composition, and size between 30 and 120 nm [30]. These exosomes are stored in cytoplasmic 
multivesicular bodies as intraluminal vesicles before secretion. A wide range of cell types are able to 
secrete exosomes such as melanocytes [31], platelets [32], trophoblasts [33], intestinal, prostate and 
intraocular epithelial cells [34–36], and, of course, also immune cells such as dendritic cells [37,38], B 
lymphocytes [39], T lymphocytes [40,41], neutrophils [42] and mast cells [43]. In addition, exosomes 
are present in blood plasma [44], colon mucosa [45], in lactating mammary glands and milk [46,47], 
human urine [48] and human bronco alveolar fluid [49]. On the other hand, exosome secretion has 
been also described in different types of tumor cells, and it has been proposed to play an important 
role in tumorigenesis and metastasis [50,51]. 
Regarding exosomes produced by activated T cells, proteomic and immunoblot studies [52,53] 
have shown the expression of proteins present in most exosomes, such as the membrane tetraspanins 
CD63 and CD81, annexins and major luminal proteins such as actin and tubulin isoforms, specific 
heat-shock proteins, enolase and GAPDH, but also of proteins related with immune function such as 
HLA-I, β2-microglobulin, components of the TCR/CD3 complex and specific integrins, among others 
(see Figure 1). Of note, the membrane-associated ATPase VCP has been detected in exosomes from 
leukemic T cells, but not in exosomes of T cells from healthy donors [52]. Other functional 
components of exosomes are regulatory miRNA [54], and in T cell exosomes it has been demonstrated 
that the enrichment in specific miRNA in T cell exosomes is dependent on the activity of another 
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major exosomal protein, the heterogeneous nuclear riboprotein A2/B1 [55]. More recently, the 
presence of DNA inside T cell exosomes has been described [56]. 
 
Figure 1. Schematic representation of a T cell derived exosome, showing the location of several of the 
most important functional proteins expressed, together with miRNA and DNA. 
For a complete repository of proteins and miRNA expressed in exosomes see also the Exocarta 
and Vesiclepedia websites http://exocarta.org/index.html; http://www.microvesicles.org. 
Exosomes produced by immune cells play a role in the activation of immune responses in many 
instances. In this line, exosomes secreted by dendritic cells and B cells, which express MHC-I and 
MHC-II on their surface, act as antigen-presenting platforms and participate in T cell priming and 
activation [39,57]. In addition, the unidirectional transfer of miRNA from T cells to antigen-presenting 
cells has been demonstrated, contributing and/or regulating the final outcome of T cell activation 
[58,59]. 
2.2. Role of Exosomes in AICD and in Pregnancy and Lactation 
Although immune exosomes play a role in T cell activation, as previously mentioned, their role 
in immune regulation processes has been more extensively studied, mainly in the context of death 
ligand-mediated T cell AICD. Although it was initially reported that the soluble form of FasL, 
generated through the metalloproteinase-mediated cleavage of the membrane protein, retained its 
cytotoxic potential [60,61], later studies demonstrated that FasL release in its soluble form due to the 
action of metalloproteases is a mechanism of functional down-regulation [62–64]. In addition, Fas 
and TRAIL receptors are physiologically expressed in the cell surface as pre-assembled oligomeric 
complexes, forming homo-trimers [65–67]. These complexes are formed through interactions of 
specific extracellular cysteine-rich domains called PLAD (pre-ligand assembly domain) [67]. 
Congruent with this, a potent pro-apoptotic activity of death ligands is dependent on the 
oligomerization of death receptor trimers in supramolecular structures [65,68]. Physiologically, this 
can only be achieved if death ligands are displayed on membrane structures: on the plasma 
membrane of effector cells [69], or on the surface of extracellular vesicles [70]  
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Our group described that both FasL and Apo2L/TRAIL are stored inside human T cell blasts in 
multivesicular bodies [71], being rapidly released to the supernatant in their bioactive form, 
associated with exosomes, upon T cell re-activation [70,71]. This observation was confirmed later on 
by other groups [72–74]. Death ligands secreted in this membrane-bound form fully conserve their 
death receptor cross-linking efficiency, correlating with their pro-apoptotic potential, thus efficiently 
participating in the down-modulation of T cell-mediated immune responses. In addition, a similar 
immunoregulatory role has been also described for exosomes produced by activated human NK cells 
[75]. 
Data obtained in mice knockout for the Wiskott-Aldrich syndrome (WAS) protein or in cytotoxic 
T lymphocyte (CTL) clones derived from Chediak-Higashi syndrome (CHS) patients gave some cues 
to demonstrate the physiological relevance of this mechanism. WAS and CHS are both primary 
immune-deficiencies, but they usually progress to autoimmunity. In the case of the WAS knockout 
mice, it was demonstrated that autoimmunity manifestations were due to the absence of functional 
FasL secretion associated with exosomes from T cells [76]. A similar situation was observed in CTL 
clones derived from CHS patients, that, although able to express FasL on their plasma membrane, 
were unable to secrete FasL associated with exosomes [77]. 
In other contexts, it has been described that T cell exosomes expressing FasL also down-
modulate dendritic cell activation, leading to the termination of immune responses [78]. In addition, 
circulating extracellular vesicles (EVs) have an immunosuppressive activity [79,80] and this activity 
is also dependent on the expression of FasL [81]. This mechanism could be important in preventing 
self and foreign antigens from causing chronic inflammation and autoimmunity. 
Another physiological setting in which exosome-mediated immune regulation is relevant is 
during the development of maternal-fetal tolerance. It has been described that FasL is secreted on the 
surface of exosomes by trophoblasts, accomplishing an important function in the attenuation of the 
immune response against the fetus and preventing spontaneous abortion [33,82]. In fact, it has been 
demonstrated that EVs derived from the serum of pregnant mice prevent further central nervous 
system injury in established experimental autoimmune encephalomyelitis [83]. 
Finally, EVs isolated from breast milk promote Treg development and proliferation, favoring 
tolerance processes [46,84]. 
2.3. Exosomes in Other Immune Regulatory Mechanisms 
The implication of exosome release in the other immune regulatory mechanisms described in 
Section 1 is less studied, but some reports reveal its importance. Noteworthy, it has been 
demonstrated that regulatory T cells (Treg) actively release immunosuppressive exosomes that 
inhibit IFN-γ secretion and the proliferation of Th1 effector cells [85]. In addition, Treg-derived 
exosomes induce the differentiation of other T cells to the Treg phenotype [86]. In this line, tumor 
exosomes, and probably other immune cell-derived exosomes, induce the differentiation of 
monocytes to monocyte-derived suppressor cells (MDSC), which suppress T cell proliferation and 
function [87]. Similarly, membrane PD-L1 [88,89] and the immunosuppressive cytokine TGF-β [90] 
have been found recently in tumor-derived exosomes, but their presence in exosomes mediating 
physiological tolerance processes has not been described yet. 
Finally, EVs from endothelial cells also modulate T cell responses and prevent chronic 
inflammation in tissues, in this case through the transfer of anti-inflammatory miRNA [91], and 
mesenchymal stem cells secrete immunosuppressive exosomes, which in fact are being used in 
clinical trials to prevent autoimmunity [92–94]. 
3. Exosomes in Autoimmune and Chronic Inflammatory Diseases 
3.1. Exosomes in Rheumatoid Arthritis and Joint Diseases 
In general, exosomes produced by inflammatory infiltrated cells are pathogenic in rheumatoid 
arthritis (RA) and other joint diseases [95,96]. Exosomes produced by synoviocytes in an 
inflammatory environment stimulate articular cells to secrete more inflammatory mediators and 
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degradative enzymes, contributing to cartilage damage [97–99]. In addition, exosomes located in the 
synovium of RA patients, probably produced by proliferating synoviocytes, contain citrullinated 
autoantigens and promote inflammation [100,101]. On the contrary, however, exosomes from 
infiltrated neutrophils into inflamed joints are protective for chondrocytes through a TGF-β1-
mediated mechanism [102] 
Regulatory FasL- and TRAIL-containing exosomes produced by activated T cells present in the 
synovium could be beneficial to prevent autoimmune damage in rheumatoid disease. It Is known 
that T cells present in the synovium of RA patients have a chronically activated phenotype, but 
contrary to normal T cell blasts, are resistant to Fas-mediated apoptosis or growth inhibition signals 
[103–105]. However, our group showed that CD8+ T cells infiltrated in the synovium of RA patients 
were susceptible to recombinant TRAIL [104]. In addition, very low amounts of bioactive FasL or 
TRAIL associated with exosomes were found in the synovial fluids of RA patients, especially in the 
late stages of the disease [104]. This observation could account for the persistence of these T cells in 
spite of their sensitivity to TRAIL (see Figure 2, left). These data suggested that bioactive, membrane-
bound TRAIL could be beneficial as an RA treatment. To verify this possibility we generated 
liposomes (large unilamellar vesicles, LUV) with a similar lipid composition as natural exosomes, to 
which recombinant TRAIL was fixed on their surface by using a Ni+2-bound coordination complex, 
termed LUV-TRAIL. These TRAIL-coated liposomes were then successfully used as a therapy in a 
rabbit model of arthritis, reducing macroscopic knee inflammation by 70%. The main effects of LUV-
TRAIL in the inflamed tissue were the complete elimination of synovial hyperplasia, together with a 
substantial reduction of the inflammatory infiltration, both mononuclear and polymorphonuclear 
(Figure 2, right) [106]. The reduction of mononuclear infiltration could be related with the effect of 
the liposomes on T cells, but the impressive effect on synovial hyperplasia could be due to direct 
effects on synoviocytes or to indirect effects on cells that produce synoviocyte-stimulating cytokines, 
but this point was not addressed in that study. We must consider that TRAIL also induces the 
proliferation of certain populations of synoviocytes in RA [107,108], suggesting that it could be a 
double-edged sword in RA treatment. However, it should be still studied if proliferative effects are 
elicited only by soluble TRAIL and if membrane- or liposome-bound TRAIL, with a higher cross-
linking efficiency, would rather induce apoptosis or cell cycle inhibition, as it has been demonstrated 
in tumor models [109–111].  
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Figure 2. Left, schematic description of the situation in an arthritic lesion with the prototypical 
pathologic hallmarks: inflammatory infiltrate, blood vessel neo-formation, synovial hyperplasia, and, 
as a consequence, bone erosion and cartilage destruction. This situation is associated with a low 
concentration of regulatory FasL and/or TRAIL-containing exosomes, probably favoring T cell 
chronic infiltration. Right, situation upon intra-articular delivery of large unilamellar vesicles 
decorated with recombinant TRAIL (LUV-TRAIL), resulting in the elimination of synovial 
hyperplasia and in a reduction of the inflammatory infiltrate (based on data in references [103,105]). 
In other studies in preclinical models, immunosuppressive exosomes produced by dendritic 
cells treated with IL-10, IL-4, or transfected with FasL also showed beneficial effects on rheumatoid 
disease [112–114]. In those studies, it was reported that the therapeutic mechanism, although 
mediated by death ligands, did not involve apoptosis. This could be probably due to cell cycle 
inhibition mediated by the induction of p21 expression in activated T cells by exosome-bound FasL 
and/or TRAIL [115–117]. This mechanism is also influencing the pathogenesis of autoimmune 
lymphoproliferative syndromes due to mutations in Fas or FasL and should be kept in mind for their 
treatment [115]. In fact, one of the most effective treatments in these syndromes, especially in severe 
cases, is rapamycin-based compounds affecting T cell cycle and proliferation [118,119]. 
3.2. Exosomes in Other Autoimmune and Chronic Inflammatory Diseases 
Less information is available on the role of exosomes in the pathogenesis and their possible use 
as a treatment of other autoimmune or chronic inflammatory diseases. 
In the case of multiple sclerosis (MS), it is known that exosomes can cross the blood-brain barrier 
and could thus contribute to spreading brain antigens to the periphery for their later presentation by 
antigen-presenting cells of the immune system [120]. However, it seems that exosomes generated 
physiologically in the Central Nervous System have a positive influence in tissue homeostasis, 
enhancing myelination and neuroprotection [120,121]. In any case, in an experimental autoimmune 
encephalomyelitis (EAE) murine model, it was clearly demonstrated that the injection of vesicles 
from microglial cells into the brain of mice developing the disease substantially increased its severity. 
In this line, mice deficient in acid sphingomyelinase, that show impaired EV secretion, were protected 
from EAE [122]. In addition, it has been shown that EVs derived from human brain microvascular 
endothelial cells are able to activate CD4+ and CD8+ T cells, probably contributing to autoantigen 
presentation [123]. These data, although limited, point to a pro-inflammatory role of EVs in MS when 
pathogenic conditions are favored. 
Another pathology in which exosomes have been implicated is in chronic inflammatory lung 
disease [124]. In the case of chronic obstructive pulmonary disease (COPD), a very frequent 
pathology mainly caused by cigarette smoking, EVs derived from human lung tissue contain miR-
210, which blocks Atg7 expression, preventing autophagy and causing myofibroblast differentiation 
and fibrosis [125]. In asthma, the expression levels of CD81, CD36 and HLA-DR in airway exosomes 
are increased [126]. The transfer of CD36+ exosomes would favor asthma progression by promoting 
inflammation through TLR4 and TLR6 complex formation [127]. Exosomes from bronco alveolar 
fluid of asthmatics contain functional leukotriene-producing enzymes, causing inflammatory 
mediator secretion by bronchial epithelial cells [128]. In this illness, exosomes produced by activated 
neutrophils or eosinophils infiltrated in the airway-surrounding tissue are also proinflammatory and 
supports the pathology [129]. 
In another allergic condition, contact hypersensitivity, it has been shown that tolerance 
induction to hapten-conjugated self-antigens was due to the secretion of exosome-like nanovesicles 
by T CD8+ suppressor cells, which contained miRNA-150 and inhibited the activation of effector T 
cells [130]. Later on, it was demonstrated the role of macrophages in this T CD8+ suppressor-mediated 
mechanism [131]. 
In type I diabetes, β pancreatic cells produce exosomes that contain autoantigens, favoring 
autoreactive T cell activation and disease [132–134]. Recently, a new mechanism of pathogenesis 
involving T-cell derived exosomes has been described [135]. In this study, the presence of specific 
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miRNA and its transfer to pancreatic βcells led to β-cell death and expression of chemokine genes, 
that would increase in turn further infiltration of activated T cells. 
The implication of exosomes in the pathogenesis of ulcerative colitis has been also suggested 
[136], but experimental data supporting this notion are scarce. The proteomic analysis of serum from 
dextran sulfate-induced acute ulcerative colitis in mice has given, however, some clues that point to 
this direction [137]. In this study, it has been shown that exosomes derived from these mice can 
induce activation of p38 and ERK in macrophages, leading to the active secretion of the pro-
inflammatory cytokine TNF-αIn addition, the mentioned proteomic study demonstrated an increase 
in acute-phase proteins and in immunoglobulins able to activate complement in those exosomes with 
respect to those of normal mice.  
Finally, the presence of pro-inflammatory exosomes has been shown in the sera of systemic 
lupus erythematosus patients. These exosomes induce the secretion of TNF-α and IFN-α in PBMC 
through a TLR-mediated mechanism [138]. In addition, several studies suggest a pathogenic role for 
renal-derived exosomes in lupus nephritis [139].  
The role of exosomes in the pathologies indicated above is summarized in Table 1. 
It should be noted that most of the immunosuppressive mechanisms present in exosomes and 
that normally regulate tolerance induction are used by tumors to evade immune surveillance and are 
susceptible to therapeutic intervention. However, this extensively studied topic exceeds the purpose 
of this review. 
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Table 1. Summary of the role of exosomes, depending on their procedence, on the development of 
the pathology indicated. +, exosomes favor pathology development; −, exosomes alleviate the 
pathology; ?, not known. 
 Exosomes Produced by Role in Pathology 
Rheumatoid arthritis Inflammatory infiltrate + 
 Synoviocytes + 
 Neutrophils − 
 T cells (death ligand containing; defective expression) − 
Multiple sclerosis Physiological CNS tissue − 
 Activated microglia + 
 Brain microvascular endothelium + 
 T cells ? 
Lung disease: COPD Lung tissue from patients + 
Asthma Airway tissue from patients + 
 Bronco alveolar fluid from patients + 
 Neutrophils/Eosinophils + 
 T cells ? 
Contact hypersensitivity T CD8+ suppressors − 
Type 1 diabetes β pancreatic cells + 
 T cells + 
Ulcerative colitis Inflamed intestinal tissue + 
 T cells ? 
SLE Sera  
Lupus nephritis Renal tissue (urine) + 
Author Contributions: Conceptualization, A.A., J.N. and L.M.-L.; Writing–Original Draft Preparation, A.A. and 
L.M.-L.; Writing–Review & Editing, A.A., A.G.-L., D.d.M., J.N. and L.M.-L.; Visualization, L.M.-L.; Supervision, 
A.A.; Project Administration, A.A., J.N. and L.M.-L.; Funding Acquisition, A.A., J.N. and L.M.-L.  
Funding: This work was supported by the Ministerio de Economía y Competitividad of Spain (SAF2016-76338-
R) to A.A. and J.N.; by Instituto de Salud Carlos III through the project PI16/00526 (LML), co-funded by European 
Regional Development Fund/European Social Fund, “Investing in your future” and by Gobierno de 
Aragón/Fondo Social Europeo (B31_17R to AA and JN). A.G.-L. was supported by a predoctoral fellowship from 
Gobierno de Aragón. 
Conflicts of interest: The authors declare no conflict of interest.  
References 
1. Kisielow, P.; Bluthmann, H.; Staerz, U.D.; Steinmetz, M.; von Boehmer, H. Tolerance in T-cell-receptor 
transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 1988, 333, 742–746. 
2. Lenardo, M.; Chan, F.K.M.; Hornung, F.; MacFarland, H.; Siegel, R.; Wang, J.; Zheng, L. Mature T 
lymphocyte apoptosis—Immune regulation in a dynamic and unpredictable antigenic enviroment. Annu. 
Rev. Immunol. 1999, 17, 221–253. 
3. Matzinger, P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 1994, 12, 991–1045. 
4. Schwartz, R.H. A cell culture model for T lymphocyte clonal anergy. Science 1990, 248, 1349–1356. 
5. Steinman, R.M.; Turley, S.; Mellman, I.; Inaba, K. The induction of tolerance by dendritic cells that have 
captured apoptotic cells. J. Exp. Med. 2000, 191, 411–416. 
6. Sakaguchi, S.; Yamaguchi, T.; Nomura, T.; Ono, M. Regulatory T Cells and Immune Tolerance. Cell 2008, 
133, 775–787. 
7. Van Parijs, L.; Abbas, A.K. Homeostasis and self-tolerance in the immune system : Turning lymphocytes 
off. Science 1998, 280, 243–248. 
8. Brunet, J.; Denizot, F.; Luciani, M.; Roux-Dosseto, M.; Suzan, M.; Mattei, M.; Golstein, P. A new member of 
the immunoglobulin superfamily--CTLA-4. Nature 1987, 328, 267–270. 
9. Krummel, M.F.; Allison, J.P. CTLA-4 engagement inhibits IL2 accumulation and cell cycle progression of 
resting T cells. J. Exp. Med. 1996, 183, 2533–2540. 
Cells 2019, 8, 154 9 of 15 
 
10. Teft, W.; Kirchhoff, M.; Madrenas, J. A Molecular Perspective of CTLA-4 Function. Annu. Rev. Immunol. 
2006, 24, 65–97. 
11. Waterhouse, P.; Penninger, J.; Timms, E.; Wakeham, A.; Shahinian, A.; Lee, K.; Thompson, C.; Griesser, H.; 
Mak, T. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4. Science 1995, 270, 
985–988. 
12. Schubert, D.; Bode, C.; Kenefeck, R.; Hou, T.; Wing, J.; Kennedy, A.; Bulashevska, A.; Petersen, B.; Schäffer, 
A.; Grüning, B.; et al., Autosomal dominant immune dysregulation syndrome in humans with CTLA4 
mutations. Nat. Med. 2014, 20, 1410–1416. 
13. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Snook, H.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.; 
Smith, A.N.; Di Genova, G.; et al., Association of the T-cell regulatory gene CTLA4 with susceptibility to 
autoimmune disease. Nature 2003, 423, 506–511. 
14. Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T., Induce expression of PD-1, a novel member of the 
immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11, 3887–3895. 
15. Boussiotis, V., Molecular and Biochemical Aspects of the PD-1 Checkpoint Path. New Eng. J. Med. 2016, 375, 
1767–1778. 
16. Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–
264. 
17. Wolchok, J. Putting the Immunologic Brakes on Cancer. Cell 2018, 175, 1452–1454. 
18. Anderson, A.; Joller, N.; Kuchroo, V. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized 
Functions in Immune Regulation. Immunity 2016, 44, 989–1004. 
19. Callan, M.F.C.; Fazou, C.; Yang, H.; Rostron, T.; Poon, K.; Hatton, C.; McMichael, A.J. CD8+ T cell selection, 
function, and death in the primary immune response in vivo. J. Clin. Invest. 2000, 106, 1251–1261. 
20. Bouillet, P.; Metcalf, D.; Huang, D.C.S.; Tarlinton, D.M.; Kay, T.W.H.; Köntgen, F.; Adams, J.M.; Strasser, 
A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to 
preclude autoimmunity. Science 1999, 286, 1735–1738. 
21. Hildeman, D.A.; Zhu, Y.; Mitchell, T.C.; Bouillet, P.; Strasser, A.; Kappler, J.; Marrack, P. Activated T cell 
death in vivo mediated by proapototic Bcl-2 family member Bim. Immunity 2002, 16, 759–767. 
22. Dhein, J.; Walczak, H.; Bäumler, C.; Debatin, K.M.; Krammer, P.H. Autocrine T-cell suicide mediated by 
APO-1 (Fas/CD95). Nature 1995, 373, 438–441. 
23. Vignaux, F.; Golstein, P. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated 
lymphocytes : A regulatory pathway? Eur. J. Immunol. 1994, 24, 923–927. 
24. Rieux-Laucat, F.; Le Deist, F.; Fischer, A. Autoimmune lymphoproliferative syndromes : Genetic defects of 
apoptosis pathways. Cell Death Differ. 2003, 10, 124–133. 
25. Anel, A.; Bosque, A.; Naval, J.; Piñeiro, A.; Larrad, L.; Alava, M.A.; Martínez-Lorenzo, M.J. Apo2L/TRAIL 
and immune regulation. Front. Biosci. 2007, 12, 2074–2084. 
26. Martínez-Lorenzo, M.J.; Alava, M.A.; Gamen, S.; Kim, J.K.; Chuntharapai, A.; Piñeiro, A.; Naval, J.; Anel, 
A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood 
T cells. Eur. J. Immunol. 1998, 28, 2714–2725. 
27. Bosque, A.; Pardo, J.; Martínez-Lorenzo, M.J.; Lasierra, P.; Larrad, L.; Marzo, I.; Naval, J.; Anel, A. Human 
CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur. J. Immunol. 
2005, 35, 1812–1821. 
28. Janssen, E.M.; Droin, N.M.; Lemmens, E.E.; Pinkoski, M.J.; Bensinger, S.J.; Ehst, B.D.; Griffith, T.S.; Green, 
D.R.; Schoenberger, S.P. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-
induced cell death. Nature 2005, 434, 88–93. 
29. Lamhamedi-Cherradi, S.E.; Zheng, S.J.; Maguschak, K.A.; Peschon, J.; Chen, Y.H. Defective thymocyte 
apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 2003, 4, 255–260. 
30. Gutiérrez-Vázquez, C.; Villarroya-Beltri, C.; Mittelbrunn, M.; Sánchez-Madrid, F. Transfer of extracellular 
vesicles during immune cell-cell interactions. Immunol. Rev. 2013, 25, 125–142. 
31. Der, J.E.; Dixon, W.T.; Jimbow, K.; Horikoshi, T. A murine monoclonal antibody against a melanosomal 
component highly expressed in early stages and common to normal and neoplastic melanocytes. Br. J. 
Cancer 1993, 67, 47–57. 
32. Heijnen, H.F.; Schiel, A.E.; Fijnheer, R.; Geuze, H.J.; Sixma, J.J. Activated platelets release two types of 
membrane vesicles : Microvesicles by surface shedding and exosomes derived from exocytosis of 
multivesicular bodies and alpha-granules. Blood 1999, 94, 3791–3799. 
Cells 2019, 8, 154 10 of 15 
 
33. Abrahams, V.M.; Straszewski-Chavez, S.L.; Guller, S.; Mor, G. First trimester trophoblast cells secrete Fas 
ligand which induces immune cell apoptosis. Mol. Hum. Reprod. 2004, 10, 55–63. 
34. McKechnie, N.M.; King, B.C.; Fletcher, E.; Braun, G. Fas-ligand is stored in secretory lysosomes of ocular 
barrier epithelia and released with microvesicles. Exp. Eye Res. 2006, 83, 304–314. 
35. Nilsson, B.O.; Jin, M.; Einarsson, B.; Persson, B.E.; Ronquist, G. Monoclonal antibodies against human 
prostasomes. Prostate 1998, 35, 178–184. 
36. van Niel, G.; Raposo, G.; Candalh, C.; Boussac, M.; Hershberg, R.; Cerf-Bensussan, N.; Heyman, M. 
Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterol. 2001, 121, 337–349. 
37. Denzer, K.; Kleijmeer, M.J.; Heijnen, H.F.G.; Stoorvogel, W.; Geuze, H.J. Exosome : From internal vesicle of 
the multivesicular body to intercellular signaling device. J. Cell Sci. 2000, 113, 3365–3374. 
38. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, 
G.; Amigorena, S. Eradication of established murine tumors using a novel cell-free vaccine : Dendritic cell-
derived exosomes. Nat. Med. 1998, 4, 594–600. 
39. Raposo, G.; Nijman, H.W.; Stoorvogel, W.; Leijendekker, R.; Harding, C.V.; Melief, C.J.M.; Geuze, H.J. B 
lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161–1172. 
40. Blanchard, N.; Lankar, D.; Faure, F.; Regnault, A.; Dumont, C.; Raposo, G.; Hivroz, C. TCR activation of 
human T cells induces the production of exosomes bearing the TCR/CD3/z complex. J. Immunol. 2002, 168, 
3235–3241. 
41. Peters, P.J.; Borst, J.; Oorschot, V.; Fukuda, M.; Krähenbühl, O.; Tschopp, J.; Slot, J.W.; Geuze, H.J. Cytotoxic 
T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J. Exp. Med. 1991, 
173, 1099–1109. 
42. Majumdar, R.; Tavakoli, T.; Parent, C. Exosomes Mediate LTB4 Release during Neutrophil Chemotaxis. 
PLoS Biol. 2016, 14, e1002336. 
43. Skokos, d.; Le Panse, S.; Villa, I.; Rousselle, J.C.; Peronet, R.; David, B.; Namame, A.; Mécheri, S. Mast cell-
dependent B and T lymphocyte activation is mediated by the secretion of immunologically active 
exosomes. J. Immunol. 2001, 166, 868–876. 
44. Hawari, F.; Rouhani, F.; Cui, X.; Yu, Z.; Buckley, C.; Kaler, M.; Levine, S. Release of full-length 55-kDa TNF 
receptor 1 in exosome-like vesicles: A mechanism for generation of soluble cytokine receptors. Proc. Natl. 
Acad. Sci. USA 2004, 101, 1297–1302. 
45. Baranov, V.; Yeung, M.M.; Hammarström, S. Expression of carcinoembrionic antigen and nonspecific 
cross-reacting 50 kDa antigen in human normal and cancerous colon mucosa: Comparative ultrastructural 
study with monoclonal antibodies. Cancer Res. 1994, 54, 3305–3314. 
46. Admyre, C.; Johansson, S.M.; Qazi, K.R.; Filén, J.J.; Lahesmaa, R.; Norman, M.; Neve, E.P.A.; Scheynius, A.; 
Gabrielson, S. Exosomes with Immune Modulatory Features Are Present in Human Breast Milk. J. Immunol. 
2007, 179, 1969–1978. 
47. Oshima, K.; Aoki, N.; Kato, T.; Kitajima, K.; Matsuda, T. Secretion of a peripheral membrane protein, MFG-
E8, as a complex with membrane vesicles. A possible role in membrane secretion. Eur. J. Biochem. 2002, 269, 
1209–1218. 
48. Pisitkun, T.; Shen, R.F.; Knepper, M.A. Identification and proteomic profiling of exosomes in human urine. 
Proc. Natl. Acad. Sci. USA 2004, 101, 13368–13373. 
49. Admyre, C.; Grunewald, J.; Thyberg, J.; Gripenbäck, S.; Tornling, G.; Eklund, A.; Scheynius, A.; 
Gabrielsson, S. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are 
present in human BAL fluid. Eur. Respir. J. 2003, 22, 578–583. 
50. Melo, S.; Luecke, L.; Kahlert, C.; Fernandez, A.; Gammon, S.; Kaye, J.; LeBleu, V.; Mittendorf, E.; Weitz, J.; 
Rahbari, N.; et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015, 
523, 177–182. 
51. Peinado, H.; Alečković, M.; Lavotshkin, S.; Matei, I.; Costa-Silva, B.; Moreno-Bueno, G.; Hergueta-Redondo, 
M.; Williams, C.; García-Santos, G.; Nitadori-Hoshino, A.; et al. Melanoma exosomes educate bone marrow 
progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18, 883–891. 
52. Bosque, A.; Dietz, L.; Gallego-Lleyda, A.; Sanclemente, M.; Iturralde, M.; Naval, J.; Alava, M.; Martínez-
Lostao, L.; Thierse, H.; Anel, A., Comparative proteomics of exosomes secreted by tumoral Jurkat T cells 
and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. 
Oncotarget 2016, 7, 29287–29305. 
Cells 2019, 8, 154 11 of 15 
 
53. Pérez-Hernández, D.; Gutiérrez-Vázquez, C.; Jorge, I.; López-Martín, S.; Ursa, A.; Sánchez-Madrid, F.; 
Vázquez, J.; Yáñez-Mó, M. The Intracellular Interactome of Tetraspanin-enriched Microdomains Reveals 
Their Function as Sorting Machineries toward Exosomes. J. Biol. Chem. 2013, 288, 11649–11661. 
54. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of 
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 
654–659. 
55. Villarroya-Beltri, C.; Gutiérrez-Vázquez, C.; Sánchez-Cabo, F.; Pérez-Hernández, D.; Vázquez, J.; Martín-
Cofreces, N.; Martínez-Herrera, D.; Pascual-Montano, A.; Mittelbrunn, M.; Sánchez-Madrid, F. Sumoylated 
hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. 
Commun. 2013, 4, 2980. 
56. Torralba, D.; Baixauli, F.; Villarroya-Beltri, C.; Fernández-Delgado, I.; Latorre-Pellicer, A.; Acín-Pérez, R.; 
Martín-Cófreces, N.; Jaso-Tamame, A.; Iborra, S.; Jorge, I.; et al. Priming of dendritic cells by DNA-
containing extracellular vesicles from activated T cells through antigen-driven contacts. Nat. Comm. 2018, 
9, 2658. 
57. Théry, C.; Duban, L.; Segura, E.; Véron, P.; Lantz, O.; Amigorena, S. Indirect activation of naïve CD4+ T cells 
by dendritic cell-derived exosomes. Nat. Immunol. 2002, 3, 1156–1162. 
58. Mittelbrunn, M.; Gutiérrez-Vázquez, C.; Villarroya-Beltri, C.; González, S.; Sánchez-Cabo, F.; González, 
M.A.; Bernad, A.; Sánchez-Madrid, F. Unidirectional transfer of microRNnA-loaded exosomes from T cells 
to antigen-presenting cells. Nat. Comm. 2011, 2, 282. 
59. Mittelbrunn, M.; Sánchez-Madrid, F. Intercellular communication: Diverse structures for exchange of 
genetic information. Nat. Rev. Mol. Cell Biol. 2012, 13, 328–335. 
60. Kayagaki, N.; Kawasaki, A.; Ebata, T.; Ohmoto, H.; Ikeda, S.; Inoue, S.; Yoshino, K.; Okumura, K.; Yagita, 
H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995, 182, 1777–1783. 
61. Tanaka, M.; Suda, T.; Takahashi, T.; Nagata, S. Expression of the functional soluble form of human Fas 
ligand in activated lymphocytes. EMBO J. 1995, 14, 1129–1135. 
62. Schneider, P.; Holler, N.; Bodmer, J.L.; Hahne, M.; Frei, K.; Fontana, A.; Tschopp, J. Conversion of 
membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its 
proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187, 1205–1213. 
63. Suda, T.; Hashimoto, H.; Tanaka, M.; Ochi, T.; Nagata, S. Membrane Fas ligand kills human peripheral 
blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997, 186, 2045–2050. 
64. Tanaka, M.; Itai, T.; Adachi, M.; Nagata, S. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4, 
31–36. 
65. Chan, F.K.M. Three is better than one: Pre-ligand receptor assembly in the regulation of TNF receptor 
signaling. Cytokine 2007, 37, 101–107. 
66. Clancy, L.; Mruk, K.; Archer, K.; Woelfel, M.; Mongkolsapaya, J.; Screaton, G.; Lenardo, M.; Chan, F. 
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) 
and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102, 18099–18104. 
67. Siegel, R.M.; Frederiksen, J.K.; Zacharias, D.A.; Chan, F.K.M.; Johnson, M.; Lynch, D.; Tsien, R.Y.; Lenardo, 
M.J. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. 
Science 2000, 288, 2354–2357. 
68. Holler, N.; Tardivel, A.; Kovacsovics-Bankowski, M.; Hertig, S.; Gaide, O.; Martinon, F.; Tinel, A.; 
Deperthes, D.; Calderara, S.; Schulthess, T.; et al. Two adjacent trimeric Fas ligands are required for Fas 
signaling and formation of a death-inducing signaling complex. Mol. Cell Biol. 2003, 23, 1428–1440. 
69. O'Reilly, L.A.; Tai, L.; Lee, L.; Kruse, E.A.; Grabow, S.; Fairlie, W.D.; Haynes, N.M.; Tarlinton, D.M.; Zhang, 
J.G.; Belz, G.T.; et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 
461, 659–663. 
70. Martínez-Lorenzo, M.J.; Anel, A.; Gamen, S.; Monleón, I.; Lasierra, P.; Larrad, L.; Piñeiro, A.; Alava, M.A.; 
Naval, J. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 
1999, 163, 1274–1281. 
71. Monleón, I.; Martínez-Lorenzo, M.J.; Monteagudo, L.; Lasierra, P.; Taulés, M.; Iturralde, M.; Piñeiro, A.; 
Larrad, L.; Alava, M.A.; Naval, J.; et al. Differential secretion of Fas ligand- or APO2 ligand/TRAIL-carrying 
microvesicles during activation-induced death of human T cells. J. Immunol. 2001, 167, 6736–6744. 
72. Alonso, R.; Mazzeo, C.; Rodriguez, M.C.; Marsh, M.; Fraile-Ramos, A.; Calvo, V.; Avila-Flores, A.; Merida, 
I.; Izquierdo, M. Diacylglycerol kinase a regulates the formation and polarisation of mature multivesicular 
Cells 2019, 8, 154 12 of 15 
 
bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes. Cell Death Differ. 
2011, 18, 1161–1173. 
73. Mazzeo, C.; Calvo, V.; Alonso, R.; Mérida, I.; Izquierdo, M. Protein kinase D1/2 is involved in the 
maturation of multivesicular bodies and secretion of exosomes in T and B lymphocytes. Cell Death Differ. 
2016, 23, 99–109. 
74. Robbins, P.; Morelli, A., Regulation of immune responses by extracellular vesicles. Nature Rev Immunol 
2014, 14, 195–208. 
75. Lugini, L.; Ceccheti, S.; Huber, V.; Luciani, F.; Macchia, G.; Spadaro, F.; Paris, L.; Abalsamo, L.; Colone, M.; 
Molinari, A.; et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol. 2013, 
189, 2833–2842. 
76. Nikolov, N.P.; Shimizu, M.; Cleland, S.; Balley, D.; Aoki, J.; Strom, T.; Schwartzberg, P.L.; Candotti, F.; 
Siegel, R.M. Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-
Aldrich syndrome protein. Blood 2010, 116, 740–747. 
77. Martín-Fernández, J.M.; Cabanillas, J.A.; Rivero-Carmena, M.; Lacasa, E.; Pardo, J.; Anel, A.; Ramírez-
Duque, P.R.; Merino, F.; Rodríguez-Gallego, C.; Regueiro, J.R. Herpesvirus saimiri-transformed CD8+ T 
cells as a tool to study Chediak-Higashi syndrome cytolytic lymphocytes. J. Leukoc. Biol. 2005, 77, 661–668. 
78. Xie, Y.; Zhang, H.; Li, W.; Deng, Y.; Munegowda, M.; Chibbar, R.; Qureshi, M.; Xiang, J. Dendritic cells 
recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through 
downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J. Immunol. 2010, 185, 5268–
5278. 
79. Ostman, S.; Taube, M.; Telemo, E. Tolerosome-induced oral tolerance is MHC dependent. Immunology 2005, 
116, 464–476. 
80. Robbins, P.; Dorronsoro, A.; Booker, C. Regulation of chronic inflammatory and immune processes by 
extracellular vesicles. J. Clin. Invest. 2016, 126, 1173–1180. 
81. Kim, S.H.; Bianco, N.R.; Shufesky, W.J.; Morelli, A.E.; Robbins, P.D. MHC Class II+ Exosomes in Plasma 
Suppress Inflammation in an Antigen-Specific and Fas Ligand/Fas-Dependent Manner. J. Immunol. 2007, 
179, 2235–2241. 
82. Frangsmyr, L.; Baranov, V.; Nagaeva, O.; Stendahl, U.; Kjellberg, L.; Mincheva-Nilsson, L. Cytoplasmic 
microvesicular form of Fas ligand in human early placenta: Switching the tissue immune privilege 
hypothesis from cellular to vesicular level. Mol. Hum. Reprod. 2005, 11, 35–41. 
83. Gatson, N.; Wiliams, J.; Powell, N.; McClain, M.; Hennon, T.; Robbins, P.; Withacre, C. Induction of 
pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific 
serum factors. J. Neuroimmunol. 2011, 230, 105–113. 
84. Arntz, O.; Pieters, B.; Oliveira, M.; Broeren, M.; Bennink, M.; de Vries, M.; van Lent, P.; Koenders, M.; van 
den Berg, W.; van der Kraan, P.; et al. Oral administration of bovine milk derived extracellular vesicles 
attenuates arthritis in two mouse models. Mol. Nutr. Food Res. 2015, 59, 1701–1712. 
85. Okoye, I.; Coomes, S.; Pelly, V.; Czieso, S.; Papayannopoulos, V.; Tolmachova, T.; Seabra, M.; Wilson, M. 
MicroRNA-Containing T-Regulatory-Cell-Derived Exosomes Suppress Pathogenic T Helper 1 Cells. 
Immunity 2014, 41, 89–103. 
86. Aiello, S.; Rocchetta, F.; Longaretti, L.; Faravelli, S.; Todeschini, M.; Cassis, L.; Pezzuto, F.; Tomasoni, S.; 
Azzollini, N.; Mister, M.; et al. Extracellular vesicles derived from T regulatory cells suppress T cell 
proliferation and prolong allograft survival. Sci. Rep. 2017, 7, 11518. 
87. Valenti, R.; Huber, V.; Iero, M.; Filipazzi, P.; Parmiani, G.; Rivoltini, L. Tumor-released microvesicles as 
vehicles of immunosupression. Cancer Res. 2007, 67, 2912–2915. 
88. Chen, G.; Huang, A.; Zhang, W.; Zhang, G.; Wu, M.; Xu, W.; Yu, Z.; Yang, J.; Wang, B.; Sun, H.; et al. 
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 
2018, 560, 382–386. 
89. Theodoraki, M.; Yerneni, S.; Hoffmann, T.; Gooding, W.; Whiteside, T. Clinical Significance of PD-L1+ 
Exosomes in Plasma of Head and Neck Cancer Patients. Clin. Cancer Res. 2018, 24, 896–905. 
90. Yen, E.; Miaw, S.; Yu, J.; Lai, I. Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers. 
Am. J. Cancer Res. 2017, 7, 2199–2208. 
91. Njock, M.; Cheng, H.; Dang, L.; Nazari-Jahantigh, M.; Lau, A.; Boudreau, E.; Roufaiel, M.; Cybulsky, M.; 
Schober, A.; Fish, J. Endothelial cells suppress monocyte activation through secretion of extracellular 
vesicles containing antiinflammatory microRNAs. Blood 2015, 125, 3202–3212. 
Cells 2019, 8, 154 13 of 15 
 
92. Arslan, F.; Chai Lai, R.; Smeets, M.; Akeroyd, L.; Choo, A.; Aguor, E.; Timmers, L.; HV, v. R.; Doevendans, 
P.; Pasterkamp, G.; Lim, S.; et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease 
oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse 
remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013, 10, 301–312. 
93. Casado, J.; Blázquez, R.; Vela, F.; Álvarez, V.; Tarazona, R.; Sánchez-Margallo, F. Mesenchymal Stem Cell-
Derived Exosomes: Immunomodulatory Evaluation in an Antigen-Induced Synovitis Porcine Model. Front 
Vet. Sci. 2017, 4, 3389. 
94. Pistoia, V.; Raffaghello, L. Mesenchymal stromal cells and autoimmunity. Int. Immunol. 2017, 29, 49–58. 
95. Tofiño-Vian, M.; Guillén, M.; Alcaraz, M. Extracellular vesicles: A new therapeutic strategy for joint 
conditions. Biochem. Pharmacol. 2018, 153, 134–146. 
96. Withrow, J.; Murphy, C.; Liu, Y.; Hunter, M.; Fulzele, S.; Hamrick, M. Extracellular vesicles in the 
pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 2016, 18, 286. 
97. Berckmans, R.; Nieuwland, R.; Kraan, M.; Schaap, M.; Pots, D.; Smeets, T.; Sturk, A.; Tak, P. Synovial 
microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis 
Res. Ther. 2005, 7, R536–R544. 
98. Lo, C.; Majkowska, I.; Nagase, H.; Di, L.I.; Troeberg, L. Microvesicles shed by oligodendroglioma cells and 
rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol. 2012, 31, 229–233. 
99. Rosenthal, A. Articular cartilage vesicles and calcium crystal deposition diseases. Curr. Opin. Rheumatol. 
2016, 28, 127–132. 
100. Cloutier, N.; Tan, S.; Boudreau, L.; Cramb, C.; Subbaiah, R.; Lahey, L.; Albert, A.; Shnayder, R.; Gobezie, 
R.; Nigrovic, P.; et al. The exposure of autoantigens by microparticles underlies the formation of potent 
inflammatory components: The microparticle-associated immune complexes. EMBO Mol. Med. 2013, 5, 
235–249. 
101. Skriner, K.; Adolph, K.; Jungblut, P.; Burmester, G. Association of citrullinated proteins with synovial 
exosomes. Arthrit Rheum. 2006, 54, 3809–3814. 
102. Headland, S.; Jones, H.; Norling, L.; Kim, A.; Souza, P.; Corsiero, E.; Gil, C.; Nerviani, A.; Dell'Accio, F.; 
Pitzalis, C.; et al. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory 
arthritis. Sci. Transl. Med. 2015, 7, 315ra190. 
103. Firestein, G.S.; Yeo, M.; Zvaifler, N.J. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 1995, 96, 
1631–1638. 
104. Martínez-Lorenzo, M.J.; Anel, A.; Sáez-Gutierrez, B.; Royo-Cañas, M.; Bosque, A.; Alava, M.A.; Piñeiro, A.; 
Lasierra, P.; Asín-Ungría, J.; Larrad, L. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. 
Clin. Immunol. 2007, 122, 28–40. 
105. Zhang, J.; Bárdos, T.; Mikecz, K.; Finnegan, A.; Glant, T.T. Impaired Fas signaling pathway is involved in 
defective T cell apoptosis in autoimmune murine arthritis. J. Immunol. 2001, 166, 4981–4986. 
106. Martinez-Lostao, L.; García-Alvarez, F.; Basáñez, G.; Alegre-Aguarón, E.; Desportes, P.; Larrad, L.; Naval, 
J.; Martínez-Lorenzo, M.J.; Anel, A. Liposome-Bound APO2L/TRAIL Is an Effective Treatment in a Rabbit 
Model of Rheumatoid Arthritis. Arthrit. Rheum. 2010, 62, 2272–2282. 
107. Audo, R.; Calmon-Hamaty, F.; Baeten, D.; Bruyer, A.; Combe, B.; Hahne, M.; Morel, J. Mechanisms and 
Clinical Relevance of TRAIL-Triggered Responses in the Synovial Fibroblasts of Patients With Rheumatoid 
Arthritis. Arthrit. Rheum. 2011, 63, 904–913. 
108. Audo, R.; Combe, B.; Coulet, B.; Morel, L.; Hahne, M. The pleiotropic effect of TRAIL on tumor-like 
synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ. 2009, 16, 
1227–1237. 
109. de Miguel, D.; Gallego-Lleyda, A.; Anel, A.; Martinez-Lostao, L. Liposome-bound TRAIL induces superior 
DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. Leuk. Res. 2015, 39, 
657–666. 
110. de Miguel, D.; Gallego-Lleyda, A.; Ayuso, J.; Pejenaute-Ochoa, D.; Jarauta, V.; Marzo, I.; Fernández, L.; 
Ochoa, I.; Conde, B.; Anel, A.; et al. High-order TRAIL oligomer formation in TRAIL-coated lipid 
nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Lett. 
2016, 383, 250–260. 
111. de Miguel, D.; Lemke, J.; Anel, A.; Walczak, H.; Martinez-Lostao, L. Onto better TRAILs for cancer 
treatment Cell Death Differ. 2015, Editorial revision. 
Cells 2019, 8, 154 14 of 15 
 
112. Kim, S.H.; Bianco, N.R.; Shufesky, W.J.; Morelli, A.E.; Robbins, P.D. Effective Treatment of Inflammatory 
Disease Models with Exosomes Derived from Dendritic Cells Genetically Modified to Express IL-4. J. 
Immunol. 2007, 179, 2242–2249. 
113. Kim, S.H.; Kim, S.; Oligino, T.J.; Robbins, P.D. Effective Treatment of Established Mouse  Collagen-
Induced Arthritis by Systemic Administration  of Dendritic Cells Genetically Modified to Express FasL. 
Mol. Ther. 2002, 6, 584–590. 
114. Yang, C.; Robbins, P.D. Immunosuppressive Exosomes: A New Approach for Treating Arthritis. Int. J. 
Rheumatol. 2012, 2012, 573528. 
115. Balomenos, D.; Shokri, R.; Daszkiewicz, L.; Martínez-A, C., On How Fas Apoptosis-independent Pathways 
Drive T cell Hyperproliferation and Lymphadenopathy in lpr Mice. Front. Immunol. 2017, 8, 237. 
116. Bosque, A.; Aguiló, J.; del Rey, M.; Paz-Artal, E.; Allende, L.; Naval, J.; Anel, A. Cell cycle regulation by 
FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative 
syndromes. J. Leukoc. Biol. 2008, 84, 488–498. 
117. Daszkiewicz, L.; Vázquez-Mateo, C.; Rackov, G.; Ballesteros-Tato, A.; Weber, K.; Madrigal-Avilés, A.; Di 
Pilato, M.; Fotedar, A.; Fotedar, R.; Flores, J.; et al. Distinct p21 requirements for regulating normal and self-
reactive T cells through IFN-g production. Sci. Rep. 2015, 5, 7691. 
118. Dragana, J.M.; Dimitrije, B.C.; Srda, J.J.; Lidija, D.B.; Nada, K.R.; Nada, K.K.J. Rapid Regression of 
Lymphadenopathy upon Rapamycin Treatment in a Child With Autoimmune Lymphoproliferative 
Syndrome. Pediatr. Blood Cancer 2009, 53, 1117–1119. 
119. Ruiz-García, R.; Mora, S.; Lozano-Sánchez, G.; Martínez-Lostao, L.; Paz-Artal, E.; Ruiz-Contreras, J.; Anel, 
A.; González-Granado, L.; Moreno, D.; Allende, L. Decreased activation-induced cell death by EBV-
transformed B cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel 
FASLG mutation. Pediatr. Res. 2015, In press. 
120. Selmaj, I.; Myckoa, M.; Raine, C.; Selmaj, K. The role of exosomes in CNS inflammation and their 
involvement in multiple sclerosis. J. Neuroimmunol. 2017, 306, 1–10. 
121. Frühbeis, C.; Fröhlich, D.; Kuo, W.; Amphornrat, J.; Thilemann, S.; Saab, A.; Kirchhoff, F.; Möbius, W.; 
Goebbels, S.; Nave, K.; et al. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-
neuron communication. PLoS Biol. 2013, 11, e1001604. 
122. Verderio, C.; Muzio, L.; Turola, E.; Bergami, A.; Novellino, L.; Ruffini, F.; Riganti, L.; Corradini, I.; 
Francolini, M.; Garzetti, L.; et al. Myeloid microvesicles are a marker and therapeutic target for 
neuroinflammation. Ann. Neurol. 2012, 72, 610–624. 
123. Wheway, J.; Latham, S.; Combes, V.; Grau, G. Endothelial microparticles interact with and support the 
proliferation of T cells. J. Immunol. 2014, 193, 3378–3387. 
124. Hough, K.; Chanda, D.; Duncan, S.; Thannickal, V.; Deshane, J., Exosomes in immunoregulation of chronic 
lung diseases. Allergy 2017, 72, 534–544. 
125. Fujita, Y.; Araya, J.; Ito, S.; Kobayashi, K.; Kosaka, N.; Yoshioka, Y.; Kadota, T.; Hara, H.; Kuwano, K.; 
Ochiya, T. Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in 
COPD pathogenesis. J. Extracell. Vesicles 2015, 4, 28388. 
126. Admyre, C.; Bohle, B.; Johansson, S.; Focke-Tejkl, M.; Valenta, R.; Scheynius, A.; Gabrielsson, S. B cell-
derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and 
produce TH2-like cytokines. J. Allergy Clin. Immunol. 2007, 120, 1418–1424. 
127. Stewart, C.; Stuart, L.; Wilkinson, K.; van Gils, J.; Deng, J.; Halle, A.; Rayner, K.; Boyer, L.; Zhong, R.; Frazier, 
W.; et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 
heterodimer. Nat. Immunol. 2010, 11, 155–161. 
128. Torregrosa-Paredes, P.; Esser, J.; Admyre, C.; Nord, M.; Rahman, Q.; Lukic, A.; Rådmark, O.; Grönneberg, 
R.; Grunewald, J.; Eklund, A.; et al. Bronchoalveolar lavage fluid exosomes contribute to cytokine and 
leukotriene production in allergic asthma. Allergy 2012, 67, 911–919. 
129. Nazimek, K.; Bryniarski, K.; Askenase, P. Functions of Exosomes and Microbial Extracellular Vesicles in 
Allergy and Contact and Delayed-Type Hypersensitivity. Int. Arch. Allergy Immunol. 2016, 171, 1–26. 
130. Bryniarski, K.; Ptak, W.; Jayakumar, A.; Pullmann, K.; Caplan, M.; Chairoungdua, A.; Lu, J.; Adams, B.; 
Sikora, E.; Nazimek, K.; et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver 
suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J. Allergy Clin. Immunol. 
2013, 132, 170–181. 
Cells 2019, 8, 154 15 of 15 
 
131. Nazimek, K.; Ptak, W.; Nowak, B.; Ptak, M.; Askenase, P.; Bryniarski, K. Macrophages play an essential 
role in antigen-specific immune suppression mediated by T CD8+ cell-derived exosomes. Immunology 2015, 
146, 23–32. 
132. Ciancaruso, C.; Phelps, E.; Pasquier, M.; Hamelin, R.; Demurtas, D.; Alibashe, A.; Piemonti, L.; Hirosue, S.; 
Swartz, M.; De Palma, M.; et al. Primary  human  and  rat  beta-cells  release  the intracellular 
autoantigens GAD65, IA-2, and pro-insulin  in  exosomes  together  with  cytokine-induced 
enhancers of immunity. Diabetes 2017, 66, 460–473. 
133. Palmisano, G.; Jensen, S.; Le Bihan, M.; Laine, J.; McGuire, J.; Pociot, F.; Larsen, M. Characterization  of  
membrane-shed microvesicles from cytokine-stimulated beta-cells using proteomics strategies. Mol. Cell 
Proteomics 2012, 11, 230–243. 
134. Vomund, A.; Zinselmeyer, B.; Hughes, J.; Calderon, B.; Valderrama, C.; Ferris, S.; Wan, X.; Kanekura, K.; 
Carriero, J.; Urano, F.; et al. Beta cells transfer vesicles containing insulin to phagocytes for presentation to 
T cells. Proc. Natl. Acad. Sci. USA 2015, 112, E5496–E5502. 
135. Guay, C.; Kruit, J.; Rome, S.; Menoud, V.; Mulder, N.; Jurdzinski, A.; Mancarella, F.; Sebastiani, G.; Donda, 
A.; Gonzalez, B.; et al. Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic Beta Cell Death and 
May Contribute to Type 1 Diabetes Development. Cell Metab. 2019, 29, 1–14. 
136. Xu, A.; Lu, J.; Ran, Z.; Zheng, Q. Exosome in intestinal mucosal immunity. J. Gastroenterol. Hepatol. 2016, 31, 
1694–1699. 
137. Wong, W.; Lee, M.; Chan, B.; Kam, R.; Zhang, G.; Lu, A.; Tai, W. Proteomic profiling of dextran sulfate 
sodium induced acute ulcerative colitis mice serum exosomes and their immunomodulatory impact on 
macrophages. Proteomics 2016, 16, 1131–1145. 
138. Lee, J.; Park, J.; Lee, E.; Lee, E.; Song, Y. Circulating exosomes from patients with systemic lupus 
erythematosus induce an proinflammatory immune response. Arthritis Res. Ther. 2016, 18, 264. 
139. Tan, L.; Wu, H.; Liu, Y.; Zhao, M.; Li, D.; Lu, Q. Recent advances of exosomes in immune modulation and 
autoimmune diseases. Autoimmunity 2016, 49, 357–365. 
 
 
© 2019 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
